Recce Pharmaceuticals Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RECEF research report →
About the company
Recce Pharmaceuticals Ltd is a biotechnology firm dedicated to the discovery, development, and commercialization of cutting-edge synthetic anti-infective treatments. The company's operations span major markets, including Australia, the United States, and the United Kingdom. Its primary drug candidate, RECCE 327, is engineered to combat severe blood infections and sepsis caused by E.
- CEO
- James Hamilton-Bray Graham
- IPO
- 2022
- HQ
- Sydney, NSW, AU
Price Chart
- Market Cap
- $80.36M
- P/E
- -3.31
- P/S
- 192.78
- P/B
- -5.82
- EV/EBITDA
- -4.42
- Div Yield
- 0.00%
- Gross Margin
- -277.34%
- Op Margin
- -3942.32%
- Net Margin
- -5378.06%
- ROE
- 279.21%
- ROIC
- 290.72%
- Revenue
- $7.51M · 9.62%
- Net Income
- $-21,428,089 · -21.33%
- EPS
- $-0.09 · 9.33%
- Op Income
- $-22,880,440
- FCF YoY
- -55.65%
- 52W High
- $0.60
- 52W Low
- $0.22
- 50D MA
- $0.22
- 200D MA
- $0.22
- Beta
- 0.39
- Avg Volume
- 110.32
Get TickerSpark's AI analysis on RECEF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RECEF coverage
Recent articles, reports, and earnings notes.
No research on RECEF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RECEF report →Similar companies
Peers in the same neighborhood.